Company

Guardant Health Inc.

GHBiotechnology

Business description

Guardant Health Inc. is a precision oncology company that specializes in liquid biopsy tests for cancer detection, monitoring, and treatment. The company’s flagship product, Guardant360, drives revenue through diagnostic testing and strategic collaborations with healthcare providers and pharmaceutical firms. Led by CEO Helmy Eltoukhy, Guardant Health has established a competitive edge in genomic profiling within the molecular diagnostics market. It is now focused on expanding its product portfolio and global reach despite facing regulatory and market challenges.

$982M
Revenue (LTM)
2
Acquisitions
-44.5%
Operating margin
Q1 2026
Latest call

Financials

View financials
Revenue (FY2025) $982M
YoY growth +32.9%
Operating margin -44.5%
Direction Expanding
Gross margin 64.5%
Net margin -42.4%

Leadership & board

View leadership
Helmy EltoukhyChairperson and Co-Chief Executive Officer
AmirAli TalasazDirector and Co-Chief Executive Officer
Ian ClarkLead Independent Director
Alex M. Azar IIDirector
Vijaya GaddeDirector
Manuel Hidalgo MedinaDirector
Meghan JoyceDirector
Steve KrognesDirector
Roberto MignoneDirector
Myrtle PotterDirector
Musa TariqDirector
Michael BellChief Financial Officer
Darya ChudovaChief Technology Officer
Craig EagleChief Medical Officer
Christopher FreemanChief Commercial Officer
Kumud KaliaChief Information Officer
Terilyn Juarez MonroeChief People Officer
John SaiaChief Legal Officer and Corporate Secretary

Share repurchases

No active share-repurchase program disclosed; the only buyback was a one-time February 2025 treasury-stock repurchase of $45.0 million tied to the Note Exchange Transaction.

$45.0 million
Repurchased (latest FY)

Competitors

Named competitors
Bio-Reference Laboratories, Inc.Laboratory Corporation of AmericaQuest Diagnostics, Inc.

Recent SEC filings

View on EDGAR
2026-05-07 Reported quarterly results View filing ↗
2026-04-27 Leadership change (directors/officers) View filing ↗
2026-02-19 Reported quarterly results View filing ↗
2026-01-12 Reported quarterly results (+1 more) View filing ↗
2025-11-07 Entered a material agreement (+3 more) View filing ↗
2025-10-29 Reported quarterly results View filing ↗
2025-09-24 Regulation FD disclosure View filing ↗
2025-09-15 Leadership change (directors/officers) View filing ↗
2025-07-30 Reported quarterly results View filing ↗
2025-06-20 Shareholder vote results View filing ↗
2025-04-30 Reported quarterly results View filing ↗
2025-04-09 Entered a material agreement (+1 more) View filing ↗

See how VectorShift works for your firm

Request Demo